CA
CHRS icon

Commerzbank Aktiengesellschaft’s Coherus Oncology CHRS Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,017
Closed -$423K – 932
2016
Q4 		$423K Sell
15,017
-4,294
-22% -$120K 0.01% 667
2016
Q3 		$517K Sell
19,311
-10,702
-36% -$292K 0.01% 560
2016
Q2 		$507 Buy
30,013
+6,945
+30% +$130K ﹤0.01% 669
2016
Q1 		$490K Buy
+23,068
New +$378K ﹤0.01% 692

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Commerzbank Aktiengesellschaft's CHRS Position: Q1 2017 in Review

Commerzbank Aktiengesellschaft sold out of Coherus Oncology (CHRS) in Q1 2017, closing a stake of 15,017 shares — an estimated $423K sold.

Commerzbank Aktiengesellschaft first reported a position in CHRS in Q1 2016 and held it in 4 quarters. The position peaked at $517K in Q3 2016. 109 funds tracked by Wall St. Rank hold CHRS as of Q1 2017.

  • Commerzbank Aktiengesellschaft reported no remaining Coherus Oncology position as of Q1 2017 after selling out during the quarter.
  • Commerzbank Aktiengesellschaft sold 15,017 Coherus Oncology shares in Q1 2017, an estimated $423K.
  • Commerzbank Aktiengesellschaft first reported a position in Coherus Oncology in Q1 2016 and held it in 4 quarters.
  • Commerzbank Aktiengesellschaft's Coherus Oncology position peaked at $517K in Q3 2016.
  • 109 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2017.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q1 2017, filed 1 May 2017.